Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:26:34.290Z.
Calculation as of: 2026-10-06T14:26:34.290Z.
Quote observation: 2026-10-06T14:24:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$1.49B
Price/OCF Ratio
98.43
TTM Avg
58.20
3Y Avg
417.88
5Y Avg
357.25
Market Cap
$1.46B
Price/OCF Ratio
9.27
TTM Avg
9.60
3Y Avg
21.94
5Y Avg
276.98
Market Cap
$1.41B
Price/OCF Ratio
78.19
TTM Avg
254.68
3Y Avg
254.68
5Y Avg
167.20
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.48B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 98.43 | 58.20 | 417.88 | 357.25 |
| Certara, Inc. (CERT)vs › | $1.50B | 18.14 | 12.61 | 22.38 | 32.95 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 9.27 | 9.60 | 21.94 | 276.98 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | 7.14 | 7.14 | 7.14 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 8.01 | 9.12 | 8.67 | 7.22 |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 78.19 | 254.68 | 254.68 | 167.20 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
